{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T08:09:06Z","timestamp":1706774946331},"reference-count":45,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T00:00:00Z","timestamp":1138147200000},"content-version":"vor","delay-in-days":1516,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2001,12]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> Tamoxifen was the first in a class of drugs now commonly referred to as selective estrogen receptor modulators or SERMs. SERMs exhibit tissue\u2010specific estrogenic agonist\/antagonist activity through their ability to bind to the estrogen receptor \u03b1 (ER) protein and interact with coregulatory proteins, thereby modulating transcription of estrogen target genes. Since its first approval by the United States Food and Drug Administration (FDA) in 1977, tamoxifen has been found to (a) lower the risk of recurrence and death for women with early\u2010stage hormone receptor\u2010positive breast cancer, irrespective of menopausal and node status or use of adjuvant chemotherapy; (b) reduce the risk of invasive breast cancer following breast conservation in women with ductal carcinoma <jats:italic>in situ<\/jats:italic> (DCIS); and (c) reduce the risk of breast cancer in high\u2010risk women. Toremifene is the only other SERM approved by the FDA for breast cancer treatment. However, it offers no clear clinical advantage over tamoxifen in the adjuvant or metastatic settings. Several other SERMs are in various phases of clinical development. In addition, strategies to combine SERMs with other endocrine therapy like ovarian suppression or aromatase inhibitors are active areas of investigations. At present, SERMs are recognized as the first targeted and relatively nontoxic medical therapy for women with high\u2010risk or steroid hormone receptor\u2010positive breast cancer.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2001.tb04005.x","type":"journal-article","created":{"date-parts":[[2010,7,21]],"date-time":"2010-07-21T00:36:25Z","timestamp":1279672585000},"page":"80-88","source":"Crossref","is-referenced-by-count":4,"title":["Use of SERMs for the Adjuvant Therapy of Early\u2010Stage Breast Cancer"],"prefix":"10.1111","volume":"949","author":[{"given":"ANTONIO C.","family":"WOLFF","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NANCY E.","family":"DAVIDSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,1,25]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811263392207"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.8.1284"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.9.1326"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.2.178"},{"key":"e_1_2_8_6_2","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.1987.5.10.1556","article-title":"Tamoxifen rechallenge: response to tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer","volume":"5","author":"Muss H.B.","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.22.3748"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.22.3758"},{"key":"e_1_2_8_9_2","first-page":"29","article-title":"A randomized double\u2010blind multicenter study of preoperative tamoxifen versus Femara (letrozole) for postmenopausal women with ER and\/or PgR positive breast cancer ineligible for breast\u2010conserving surgery: correlation of clinical response with tumor expression and proliferation [abstract 14]","volume":"64","author":"Ellis M.J.","year":"2000","journal-title":"Breast Cancer Res. Treat."},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11423-4"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.11.776"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7011.977"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198902233200802"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.21.1529"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.7.527"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.18.1371"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)85012-5"},{"key":"e_1_2_8_18_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(98)04394-3","article-title":"Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women\u2014Italian Tamoxifen Prevention Study","volume":"352","author":"Veronesi U.","year":"1998","journal-title":"Lancet"},{"key":"e_1_2_8_19_2","first-page":"117","article-title":"The Scottish trial of adjuvant tamoxifen in node\u2010negative breast cancer: the Scottish Cancer Trials Breast Group","volume":"311","author":"Stewart H.J.","year":"1992","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.356"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.24.1828"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.5.1474"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905133401902"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.441"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)06341-2"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05036-9"},{"key":"e_1_2_8_27_2","first-page":"4534","article-title":"Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats","volume":"53","author":"Hard G.C.","year":"1993","journal-title":"Cancer Res."},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.20.1552"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.4.4688"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.2.345"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006250213357"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.20.3487"},{"key":"e_1_2_8_33_2","first-page":"1070","article-title":"Idoxifene: report of a phase I study in patients with metastatic breast cancer","volume":"55","author":"Coombes R.C.","year":"1995","journal-title":"Cancer Res."},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00689679"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.7.637"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.23.2189"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2047::AID-CNCR10>3.0.CO;2-E"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1939"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006348907994"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3172"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91156-1"},{"key":"e_1_2_8_42_2","first-page":"27","article-title":"Comparison of efficacy and tolerability of fulvestrant (Faslodex) with anastrozole (Arimidex) in post\u2010menopausal (PM) women with advanced breast cancer (ABC)\u2014preliminary results [abstract 6]","volume":"64","author":"Howell A.","year":"2000","journal-title":"Breast Cancer Res. Treat."},{"key":"e_1_2_8_43_2","first-page":"a7","article-title":"On behalf of the North American Faslodex Investigator Group: a double\u2010blind randomized trial of Faslodex (fulvestrant) with Arimidex (anastrozole) in post\u2010menopausal (PM) women with advanced breast cancer (ABC) [abstract 7]","volume":"64","author":"Osborne C.K.","year":"2000","journal-title":"Breast Cancer Res. Treat."},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.343"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.275"},{"key":"e_1_2_8_46_2","first-page":"86a","article-title":"Fenretinide (FEN) vs","volume":"19","author":"Cobleigh M.A.","year":"2000","journal-title":"placebo in postmenopausal breast cancer patients receiving adjuvant tamoxifen (TAM), an Eastern Cooperative Oncology Group phase III intergroup trial (EB193, INT-0151) [abstract 328]. Proc. Am. Soc. Clin. Oncol."}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2001.tb04005.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2001.tb04005.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T02:05:42Z","timestamp":1695607542000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2001.tb04005.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["10.1111\/j.1749-6632.2001.tb04005.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2001.tb04005.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}